Literature DB >> 25786716

Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model.

Tatsuaki Tagami1, Amr S Abu Lila, Mariko Matsunaga, Naoto Moriyoshi, Hiroyuki Nakamura, Kazuya Nakamura, Takuya Suzuki, Yusuke Doi, Tatsuhiro Ishida, Hiroshi Kiwada.   

Abstract

Efficient systemic siRNA delivery to cells in the target tissue is a current critical challenge in the drug delivery field. Several studies have demonstrated that nanoparticles such as polyethylene glycol (PEG)-coated siRNA-lipoplexes may enhance the systemic delivery of siRNA to tumor. However, the disordered tumor microenvironment still poses a potential impediment with respect to the efficient delivery of PEG-coated siRNA-lipoplexes. Recently, we showed that metronomic S-1 dosing (daily oral administration) enhanced the accumulation of PEG-coated siBcl-2-lipoplex in DLD-1 solid tumor mouse model. In this study, to extend our work, we investigated the effect of metronomic S-1 dosing on the intratumoral accumulation and, thereby, therapeutic efficacy of PEG-coated siAgo2-lipoplex in Lewis lung carcinoma cells (LLCC) solid tumor mouse model. Also, we tried to elucidate the probable mechanism of the enhanced intratumoral accumulation of PEG-coated siRNA-lipoplexes induced by S-1 combination therapy. Results showed that metronomic S-1 dosing improved systemic delivery of intravenously injected PEG-coated siAgo2-lipoplexes into a LLCC solid tumor. In addition, the combined therapy of S-1 and PEG-coated siRNA-lipoplexes resulted in potent tumor growth suppression. These findings offer proof-of-concept for the improved systemic delivery of PEG-coated siRNA-lipoplexes by metronomic S-1 dosing in whatever tumor model used, and this may pose a promising therapeutic strategy to conquer cancer progression.

Entities:  

Year:  2012        PMID: 25786716     DOI: 10.1007/s13346-012-0059-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  41 in total

Review 1.  Potential use of RNA interference in cancer therapy.

Authors:  Connor Phalon; Donald D Rao; John Nemunaitis
Journal:  Expert Rev Mol Med       Date:  2010-08-18       Impact factor: 5.600

Review 2.  Efficient and targeted delivery of siRNA in vivo.

Authors:  Min Suk Shim; Young Jik Kwon
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

3.  Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.

Authors:  Kazushi Suzuki; Toshio Kokuryo; Takeshi Senga; Yukihiro Yokoyama; Masato Nagino; Michinari Hamaguchi
Journal:  Cancer Sci       Date:  2010-01-20       Impact factor: 6.716

4.  Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.

Authors:  Terence C Tang; Shan Man; Christina R Lee; Ping Xu; Robert S Kerbel
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

5.  A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

Authors:  Kazuya Nakamura; Amr S Abu Lila; Mariko Matsunaga; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

7.  Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy.

Authors:  Won Jong Kim; Chien-Wen Chang; Minhyung Lee; Sung Wan Kim
Journal:  J Control Release       Date:  2007-01-09       Impact factor: 9.776

8.  A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.

Authors:  Emi Shiraga; Jose Mario Barichello; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Int J Pharm       Date:  2007-11-17       Impact factor: 5.875

9.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

Authors:  Gunter Meister; Markus Landthaler; Agnieszka Patkaniowska; Yair Dorsett; Grace Teng; Thomas Tuschl
Journal:  Mol Cell       Date:  2004-07-23       Impact factor: 17.970

10.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.

Authors:  Mitsunobu R Kano; Younsoo Bae; Caname Iwata; Yasuyuki Morishita; Masakazu Yashiro; Masako Oka; Tomoko Fujii; Akiyoshi Komuro; Kunihiko Kiyono; Michio Kaminishi; Kosei Hirakawa; Yasuyoshi Ouchi; Nobuhiro Nishiyama; Kazunori Kataoka; Kohei Miyazono
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-16       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.